Comparative Pharmacology
Head-to-head clinical analysis: STENDRA versus YESAFILI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STENDRA versus YESAFILI.
STENDRA vs YESAFILI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of phosphodiesterase type 5 (PDE5), enhancing cyclic guanosine monophosphate (cGMP) accumulation in corpus cavernosum, leading to smooth muscle relaxation and increased penile blood flow.
Selective estrogen receptor degrader (SERD) that binds to estrogen receptors (ER), inducing a conformational change leading to receptor degradation and inhibition of estrogen-dependent tumor growth.
50 mg orally once daily as needed, 1 hour before sexual activity. Maximum dose 100 mg. Maximum frequency once daily.
10 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 4 hours in healthy subjects; may be prolonged in hepatic impairment (Child-Pugh B: up to 6 hours) or with concomitant CYP3A4 inhibitors.
Terminal elimination half-life of 3–5 hours in healthy adults; prolonged in hepatic impairment (up to 8–10 hours), requiring dose adjustment.
Fecal (approximately 63%) and renal (approximately 21%) as metabolites; less than 2% excreted unchanged in urine.
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for approximately 2% of the dose, with biliary/fecal elimination as the major route.
Category C
Category C
PDE5 Inhibitor
PDE5 Inhibitor